findmyKOL

Naresh Solankhi, MD

Basic profile

University of Louisville

ORCIDNone on fileNPI
RegionLouisville, KY · SoutheastSpecialtyInterventional CardiologyFocusCardiology
Active KOLEmergingfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Naresh Solankhi is a Cardiology physician affiliated with University of Louisville. OpenAlex indexes 30 publications with 1,629 citations (h-index 11).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
30publications

Distinct works indexed by OpenAlex.

1,629citations

Total citations across indexed works.

11h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
12companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

12 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    72.7%
    Beta blocker16.9%
    Metoprolol Succinate47%Carvedilol25%Metoprolol Tartrate21%Atenolol5%Toprol Xl2%
    Part D<11 patients
    Statin12.2%
    Atorvastatin Calcium77%Rosuvastatin Calcium20%Simvastatin4%
    Part D<11 patients

    + 14 more classes in this area

  • Blood & clotting

    19.9%
    P2Y12 inhibitor11.6%
    Clopidogrel82%Brilinta18%
    Part D89 patients
    Factor Xa inhibitor7.2%
    Eliquis79%Xarelto21%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    7.4%
    SGLT2 inhibitor4.9%
    Farxiga83%Jardiance17%
    Part D<11 patients
    Potassium supplement2.2%
    Potassium Chloride100%
    Part D15 patients

    + 1 more class in this area

Where care is delivered (Part B)61.3% facility · 38.7% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”